ci 994 has been researched along with Benign Neoplasms in 7 studies
tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells
tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Capecitabine was administered in twice daily divided doses, and CI-994 was given as a single daily dose." | 2.71 | A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. ( Janisch, L; Kimmel, KA; Kindler, HL; Macek, TA; Olson, SC; Ratain, MJ; Schilsky, RL; Undevia, SD; Vogelzang, NJ, 2004) |
| "To determine maximum tolerated dose of CI-994, a novel oral histone deacetylase inhibitor, in combination with carboplatin and paclitaxel in patients with advanced solid tumors." | 2.71 | Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. ( Cunningham, C; Grove, W; Kraker, A; Nemunaitis, J; Olivares, J; Olson, S; Pauer, LR; Williams, A, 2004) |
| " Dosage escalation proceeded in 2 phases; an Acute Dosing Phase (n = 11) to define the MTD for CI-994 administered over 2 weeks and a Chronic Dosing Phase (n = 29) to define the MTD for daily administration for 8 weeks." | 2.70 | Chronic oral administration of CI-994: a phase 1 study. ( Flaherty, L; Foster, BJ; Heilbrun, LK; LoRusso, PM; Meyer, M; Prakash, S; Radulovic, L; Valdivieso, M; Wozniak, A; Zalupski, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, R | 1 |
| Yao, Y | 1 |
| Tang, P | 1 |
| Chen, G | 1 |
| Liu, X | 1 |
| Yun, F | 1 |
| Cheng, C | 1 |
| Wu, X | 1 |
| Yuan, Q | 1 |
| Dong, G | 1 |
| Chen, W | 1 |
| Wang, X | 1 |
| Yang, X | 1 |
| Xu, T | 1 |
| Wang, P | 1 |
| Zhang, W | 1 |
| Rao, Y | 1 |
| Miao, C | 1 |
| Sheng, C | 1 |
| Smalley, JP | 1 |
| Baker, IM | 1 |
| Pytel, WA | 1 |
| Lin, LY | 1 |
| Bowman, KJ | 1 |
| Schwabe, JWR | 1 |
| Cowley, SM | 1 |
| Hodgkinson, JT | 1 |
| Undevia, SD | 1 |
| Kindler, HL | 1 |
| Janisch, L | 1 |
| Olson, SC | 1 |
| Schilsky, RL | 1 |
| Vogelzang, NJ | 1 |
| Kimmel, KA | 1 |
| Macek, TA | 1 |
| Ratain, MJ | 1 |
| Pauer, LR | 1 |
| Olivares, J | 1 |
| Cunningham, C | 1 |
| Williams, A | 1 |
| Grove, W | 1 |
| Kraker, A | 1 |
| Olson, S | 1 |
| Nemunaitis, J | 1 |
| Dizon, DS | 1 |
| Prakash, S | 1 |
| Foster, BJ | 1 |
| Meyer, M | 1 |
| Wozniak, A | 1 |
| Heilbrun, LK | 1 |
| Flaherty, L | 1 |
| Zalupski, M | 1 |
| Radulovic, L | 1 |
| Valdivieso, M | 1 |
| LoRusso, PM | 1 |
3 trials available for ci 994 and Benign Neoplasms
| Article | Year |
|---|---|
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2004 |
Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors.
Topics: Acetylation; Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy | 2004 |
Chronic oral administration of CI-994: a phase 1 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Hum | 2001 |
4 other studies available for ci 994 and Benign Neoplasms
| Article | Year |
|---|---|
Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Topics: A549 Cells; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening | 2017 |
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Death; Cell Line, Tumor; Drug Discovery; | 2017 |
Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells.
Topics: Apoptosis; Chimera; Histone Deacetylase 1; Histone Deacetylases; Humans; Ligands; Neoplasms; Proteol | 2022 |
Incorporating targeted treatments into standard regimens: whither the role of established doses?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Drug Therapy, Combination; | 2004 |